Conexeu Sciences (NASDAQ:CNXU) Announces Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Conexeu Sciences (NASDAQ:CNXU) announced its earnings results on Monday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.19), Zacks reports.

Conexeu Sciences Price Performance

Conexeu Sciences stock opened at $5.00 on Tuesday. Conexeu Sciences has a fifty-two week low of $4.19 and a fifty-two week high of $18.79. The firm has a market capitalization of $133.80 million and a price-to-earnings ratio of -45.45. The firm has a fifty day moving average price of $7.97.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CNXU. Zacks Research upgraded shares of Conexeu Sciences to a “hold” rating in a report on Monday, June 29th. Weiss Ratings initiated coverage on shares of Conexeu Sciences in a report on Monday, August 17th. They issued a “sell (e-)” rating for the company. Wall Street Zen raised Conexeu Sciences to a “hold” rating in a research report on Saturday, May 30th. Finally, HC Wainwright initiated coverage on Conexeu Sciences in a report on Monday, June 22nd. They set a “buy” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Conexeu Sciences presently has a consensus rating of “Hold” and an average target price of $20.00.

Insider Buying and Selling

In related news, Director Lynn Sebastian Purcell purchased 202,500 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was bought at an average price of $0.80 per share, with a total value of $162,000.00. Following the completion of the transaction, the director owned 2,734,240 shares of the company’s stock, valued at approximately $2,187,392. This represents a 8.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.